Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Amikacin in Ventilator-Associated Pneumonia
NCT07369336Phase 4Completed
- Sponsor
- Postgraduate Medical Institute
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of amikacin liposome inhalation suspension in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Postgraduate Medical Institute. Primary endpoint: Duration of invasive mechanical ventilation up to 28 days. Started Jan 2024; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07369336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369336.